Related Experiment Videos
[Evaluation of pindolol absorption in malabsorption syndromes]
Gastroenterologie Clinique Et Biologique
|April 1, 1983
Summary
Drug absorption of pindolol was investigated in patients with intestinal diseases. While intravenous doses showed similar plasma concentrations, oral absorption was delayed or decreased in some patients, suggesting potential intestinal disease impact.
Area of Science:
- Pharmacology
- Gastroenterology
- Clinical Medicine
Background:
- Drug absorption studies in intestinal diseases are limited.
- Pindolol is well-absorbed with low hepatic extraction, making it suitable for absorption studies.
Purpose of the Study:
- To investigate the oral and intravenous absorption of pindolol in patients with intestinal malabsorption.
- To compare pindolol absorption in healthy volunteers versus patients with coeliac disease or short bowel syndrome.
Main Methods:
- Administered single oral and intravenous doses of pindolol to 6 healthy volunteers and 13 patients with intestinal malabsorption.
- Monitored plasma concentrations and 54-hour urinary excretion for both groups.
- Analyzed data considering disease type (coeliac disease, short bowel syndrome) and severity.
Main Results:
- Pindolol plasma concentrations after intravenous administration were similar between patients and controls.
- Mean blood levels after oral dosing were not significantly different overall, but absorption was slow/delayed in 8/13 patients.
- Two patients showed decreased overall oral absorption; intravenous parameters remained comparable to controls.
Conclusions:
- Intestinal diseases may cause delayed or reduced oral absorption of pindolol, despite similar intravenous pharmacokinetics.
- The observed absorption abnormalities are linked to the diseased intestine but not directly to the extent of disease or functional impairment.